Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency

Kirsten I Marchand, Eugenia Oviedo-Joekes, Daphne Guh, Suzanne Brissette, David C Marsh, Martin T Schechter, Kirsten I Marchand, Eugenia Oviedo-Joekes, Daphne Guh, Suzanne Brissette, David C Marsh, Martin T Schechter

Abstract

Background: Substitution with opioid-agonists (e.g., methadone) has shown to be an effective treatment for chronic long-term opioid dependency. Patient satisfaction with treatment has been associated with improved addiction treatment outcomes. However, there is a paucity of studies evaluating patients' satisfaction with Opioid Substitution Treatment (OST). In the present study, participants' satisfaction with OST was evaluated at 3 and 12 months. We sought to test the relationship between satisfaction and patients' characteristics, the treatment modality received and treatment outcomes.

Methods: Data from a randomized controlled trial, the North American Opiate Medication Initiative (NAOMI), conducted in Vancouver and Montreal (Canada) between 2005-2008, was analyzed. The NAOMI study compared the effectiveness of oral methadone vs. injectable diacetylmorphine over 12 months. A small sub-group of patients received injectable hydromorphone on a double blind basis with diacetylmorphine. The Client Satisfaction Questionnaire (CSQ-8) was used to measure satisfaction with treatment. CSQ-8 scores, as well as retention and response to treatment, did not differ between those receiving hydromorphone and diacetylmorphine at 3 or 12 months assessments; therefore, these two groups were analyzed together as the 'injectable' treatment group.

Results: A total of 232 (92%) and 237 (94%) participants completed the CSQ-8 at 3 and 12 months, respectively. Participants in both groups were highly satisfied with treatment. Independent of treatment group, participants satisfied with treatment at 3 months were more likely to be retained at 12 months. Multivariate analysis indicated that satisfaction was greater among those randomized to the injection group after controlling for treatment effectiveness. Participants who were retained, responded to treatment, and had fewer psychological symptoms were more satisfied with treatment. Finally, open-ended comments were made by 149 (60.3%) participants; concerns about the randomization process and the study ending were most commonly reported by participants receiving the oral and injectable medications, respectively.

Conclusions: The higher satisfaction among those receiving medically prescribed injectable diacetylmorphine (or hydromorphone) supports current evidence regarding the attractiveness of this treatment for long-term, opioid-dependent individuals not benefiting sufficiently from other treatments. In addition, the measurement of treatment satisfaction provides valuable information about participants at risk of relapse and in need of additional services.

Trial registration: ClinicalTrials.gov Identifier: NCT00175357.

References

    1. Kuyper LM, Hogg RS, Montaner JSG, Schechter MT, Wood E. The Cost of Inaction on Hiv Transmission Among Injection Drug Users and the Potential for Effective Interventions. J Urban Health. 2004;81:655–660.
    1. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008. p. CD004145.
    1. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–6. doi: 10.1016/S0140-6736(98)05356-2.
    1. Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51:635–46.
    1. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–9. doi: 10.1001/jama.269.15.1953.
    1. Amato L, Davoli M, A Perucci C, Ferri M, Faggiano F, P Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321–9. doi: 10.1016/j.jsat.2005.02.007.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. p. CD002209.
    1. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98:673–84. doi: 10.1046/j.1360-0443.2003.00354.x.
    1. Health Canada. Best practices in methadone maintenance treatment. Ontario, Canada.: Minister of Public Works and Government Services Canada; 2002.
    1. The College of Physicians of Ontario. Methadone maintenance guidelines. 2005.
    1. Bukstein OG. Satisfaction with treatment for attention-deficit/hyperactivity disorder. Am J Manag Care. 2004;10:S107–16.
    1. Saila T, Mattila E, Kaila M, Aalto P, Kaunonen M. Measuring patient assessments of the quality of outpatient care: a systematic review. J Eval Clin Pract. 2008;14:148–54. doi: 10.1111/j.1365-2753.2007.00824.x.
    1. Lehman AF, Zastowny TR. Patient satisfaction with mental health services: a meta-analysis to establish norms. Eval Program Plann. 1983;6:265–74. doi: 10.1016/0149-7189(83)90006-X.
    1. Batchelor C, Owens DJ, Read M, Bloor M. Patient satisfaction studies: methodology, management and consumer evaluation. Int J Health Care Qual Assur. 1994;7:22–30. doi: 10.1108/09526869410074720.
    1. Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. Gut. 2004;53(Suppl 4):40–4. iv.
    1. Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. Issues in the measurement of satisfaction with treatment. Am J Manag Care. 1997;3:579–94.
    1. Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008;27:671–8. doi: 10.1080/09595230801935706.
    1. Perez de los Cobos J, Fidel G, Escuder G, Haro G, Sanchez N, Pascual C, Valderrama JC, Valero S, Trujols J. A satisfaction survey of opioid-dependent clients at methadone treatment centres in Spain. Drug Alcohol Depend. 2004;73:307–13. doi: 10.1016/j.drugalcdep.2003.11.001.
    1. Perez de Los Cobos J, Trujols J, Valderrama JC, Valero S, Puig T. Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction with treatment. Drug Alcohol Depend. 2005;79:405–12. doi: 10.1016/j.drugalcdep.2005.03.021.
    1. Sell L, Zador D. Patients prescribed injectable heroin or methadone -their opinions and experiences of treatment. Addiction. 2004;99:442–9. doi: 10.1111/j.1360-0443.2003.00668.x.
    1. King VL, Stoller KB, Hayes M, Umbricht A, Currens M, Kidorf MS, Carter JA, Schwartz R, Brooner RK. A multicenter randomized evaluation of methadone medical maintenance. Drug Alcohol Depend. 2002;65:137–48. doi: 10.1016/S0376-8716(01)00155-7.
    1. King VL, Kidorf MS, Stoller KB, Schwartz R, Kolodner K, Brooner RK. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J Subst Abuse Treat. 2006;31:385–93. doi: 10.1016/j.jsat.2006.05.014.
    1. Kumar RM, Rajwal M. Survey of client satisfaction with methadone maintenance programmes [abstract] Psychiatric Bulletin. 2006. pp. 16–18.
    1. Corrigan PW. Consumer satisfaction with institutional and community care. Community Ment Health J. 1990;26:151–65. doi: 10.1007/BF00752392.
    1. Morris ZS, Gannon M. Drug misuse treatment services in Scotland: predicting outcomes. Int J Qual Health Care. 2008;20:271–6. doi: 10.1093/intqhc/mzn019.
    1. Kelly SM, O'Grady KE, Brown BS, Mitchell SG, Schwartz RP. The Role of Patient Satisfaction in Methadone Treatment. American Journal of Drug & Alcohol Abuse. 2010;36:150–154. doi: 10.3109/00952991003736371.
    1. Zhiwei Zhang, Gerstein DR, Friedmann PD. Patient Satisfaction and Sustained Outcomes of Drug Abuse Treatment. Journal of Health Psychology. 2008;13:388–400. doi: 10.1177/1359105307088142.
    1. McLellan AT, Hunkeler E. Patient satisfaction and outcomes in alcohol and drug abuse treatment. Psychiatr Serv. 1998;49:573–5.
    1. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361:777–86. doi: 10.1056/NEJMoa0810635.
    1. Oviedo-Joekes E, Nosyk B, Marsh D, Guh D, Brissette S, Gartry C, Krausz M, Anis A, Schechter MT. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI Study. Clinical Trials. 2009. pp. 261–271.
    1. Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, Krausz M, Anis A, Schechter MT. The North American Opiate Medication Initiative (NAOMI): Profile of Participants in North America's First Trial of Heroin-Assisted Treatment. J Urban Health. 2008;85:812–25. doi: 10.1007/s11524-008-9312-9.
    1. Oviedo-Joekes E, Marsh D, Guh D, Brissette S, Schechter MT. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency. J Opioid Manag. in press .
    1. Oviedo-Joekes E, Guh D, Brissette S, Marchand K, Marsh D, Chettiar J, Nosyk B, Krausz M, Anis A, Schechter MT. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend. 2010.
    1. Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. pp. 208–210.
    1. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857–67. doi: 10.1046/j.1360-0443.1998.9312185711.x.
    1. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2:197–207. doi: 10.1016/0149-7189(79)90094-6.
    1. Nguyen TD, Attkisson CC, Stegner BL. Assessment of patient satisfaction: development and refinement of a service evaluation questionnaire. Eval Program Plann. 1983;6:299–313. doi: 10.1016/0149-7189(83)90010-1.
    1. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi: 10.1186/1477-7525-2-12.
    1. O'Regan C, Ryan M. Patient satisfaction with an emergency department psychiatric service. I Int J Health Care Qual Assur. 2009;22:525–34. doi: 10.1108/09526860910975616.
    1. De Wilde EF, Hendriks VM. The Client Satisfaction Questionnaire: psychometric properties in a Dutch addict population. Eur Addict Res. 2005;11:157–62. doi: 10.1159/000086396.
    1. Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83:218–24. doi: 10.1016/j.drugalcdep.2005.11.020.
    1. Ilgen MA, Trafton JA, Humphreys K. Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. Drug Alcohol Depend. 2006;82:187–193. doi: 10.1016/j.drugalcdep.2005.09.005.
    1. Trafton JA, Tracy SW, Oliva EM, Humphreys K. Different Components of Opioid-Substitution Treatment Predict Outcomes of Patients With and Without a Parent With Substance-Use Problems. J Stud Alcohol Drugs. 2007;68:165–172.
    1. Ward J. World Health Organization (WHO), Evaluation of Psychoactive Substance Use Disorder Treatment: Workbook 6 Client Satisfaction Evaluations. Geneva: World Health Organization; 2000. Part C. The case of community methadone treatment programs; pp. 32–38.
    1. Greenley JR, Schoenherr RA. Organization effects on client satisfaction with humaneness of service. J Health Soc Behav. 1981;22:2–18. doi: 10.2307/2136364.
    1. Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004;55:767–74. doi: 10.1176/appi.ps.55.7.767.
    1. Ruggeri M, Dall'Agnola R, Agostini C, Bisoffi G. Acceptability, sensitivity and content validity of the VECS and VSSS in measuring expectations and satisfaction in psychiatric patients and their relatives. Soc Psychiatry Psychiatr Epidemiol. 1994;29:265–76. doi: 10.1007/BF00802049.
    1. Hser YI, Huang D, Chou CP, Anglin MD. Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval Rev. 2007;31:548–63. doi: 10.1177/0193841X07307315.
    1. Bjorngaard JH, Rustad AB, Kjelsberg E. The prisoner as patient - a health services satisfaction survey. BMC Health Serv Res. 2009;9:176. doi: 10.1186/1472-6963-9-176.
    1. Soergaard KW, Nivison M, Hansen V, Oeiesvold T. Treatment needs and acknowledgement of illness - importance for satisfaction with psychiatric inpatient treatment. BMC Health Serv Res. 2008;8:103. doi: 10.1186/1472-6963-8-103.
    1. Aharony L, Strasser S. Patient satisfaction: what we know about and what we still need to explore. Med Care Rev. 1993;50:49–79. doi: 10.1177/002570879305000104.
    1. Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Nosyk B, Krausz M, Anis A, Christian WM, Spittal P, Schechter MT. Characteristics and response to treatment among Aboriginal people receiving heroin-assisted treatment. Can J Public Health. 2010;101:210–2.
    1. Callon C, Wood E, Marsh D, Li K, Montaner J, Kerr T. Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver. J Opioid Manag. 2006;2:35–41.
    1. Canadian Aboriginal AIDS Network. Joining the Circle, Phase II. 2004.
    1. Donovan DM, Kadden RM, DiClemente CC, Carroll KM. Client satisfaction with three therapies in the treatment of alcohol dependence: results from project MATCH. Am J Addict. 2002;11:291–307. doi: 10.1080/10550490290088090.
    1. Carlson MJ, Gabriel RM. Patient satisfaction, use of services, and one-year outcomes in publicly funded substance abuse treatment. Psychiatr Serv. 2001;52:1230–6. doi: 10.1176/appi.ps.52.9.1230.
    1. Thomson CL, Morley KC, Teesson M, Sannibale C, Haber PS. Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug Alcohol Rev. 2008;27:115–22. doi: 10.1080/09595230701829561.
    1. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to Participation in Randomised Controlled Trials: A Systematic Review. J Clin Epidemiol. 1999;52:1143–1156. doi: 10.1016/S0895-4356(99)00141-9.
    1. McCarthy-Keith D, Nurudeen S, Armstrong A, Levens E, Nieman LK. Recruitment and retention of women for clinical leiomyoma trials. Contemp Clin Trials. 2010;31:44–8. doi: 10.1016/j.cct.2009.09.007.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe